title: Successful response of severe neonatal gram-negative infection to treatment with aztreonam.
abstract: Aztreonam was administered to 25 neonates (16 term, 9 premature) with clinically and bacteriologically proved gram-negative infections. Ten patients had meningitis, 9 had septicemia and 6 had urinary tract infections. Patients were between 1 and 28 days of age. Aztreonam was administered intravenously in doses ranging from 40 to 120 mg/kg/day for 10-30 days, depending on the causative organism. All CSF, blood and urine cultures were sterile 48 h after drug treatment had begun. There was no incidence of bacteriologic relapse. Body temperature returned to normal in 96% of patients within 3-4 days of therapy. Aztreonam was well tolerated. One infant experience nausea and vomiting, but no patient was withdrawn from therapy due to adverse reactions.
authors.affiliation: Aghia Sophia Children's Hospital, Athens; Greece.
authors.forename: A
authors.initials: A
authors.lastname: Constantopoulos
authors.forename: L
authors.initials: L
authors.lastname: Thomaidou
authors.forename: H
authors.initials: H
authors.lastname: Loupa
authors.forename: G
authors.initials: G
authors.lastname: Papoulias
mesh_terms: D001398:Aztreonam / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D006090:Gram-Negative Bacteria; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D008581:Meningitis / Q000188:drug therapy; D011379:Prognosis; D018805:Sepsis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
chemical_list: D001398:Aztreonam